Frequência do polimorfismo cyp2c19*17 em um grupo de pacientes com transtorno depressivo maior tratados com citalopram ou escitalopram atendidos no Hospital Universitário Onofre Lopes

Abstract

Introduction: Major depressive disorder (MDD) is an extremely disabling disease that affects millions of people worldwide. Citalopram and escitalopram are antidepressants that belong to the class of selective serotonin reuptake inhibitors (SSRIs), metabolised primarily by CYP2C19, a highly polymorphic enzyme that has approximately 2000 single reference nucleotide polymorphisms (rsSNPs). The aim of this study was to verify the frequency of CYP2C19 * 17 (rs12248560) polymorphism in a group of patients diagnosed with major depressive disorder treated with citalopram or escitalopram assisted at Onofre Lopes University Hospital (HUOL). Methodology: Sixty-nine (69) subjects were included in the study, 29 of them were patients from the HUOL MDD psychiatric outpatient clinic. Blood samples were collected and DNA was extracted from these samples from peripheral blood leukocytes using the QiaAmp DNA Blood Mini Kit® (Qiagen, Hilden, Germany), according to the manufacturer's protocol. Subsequently, genotyping was performed by TaqMan® allelic discrimination in a real-time PCR system. Results: nineteen patients (65.5%), were not carriers of the T-allele conferring the ultra-fast metabolizer characteristic, nine (31.1%) were heterozygous (CT) and only one patient (3.4%) was mutated homozygote ( TT). An allele frequency (T) of 19% was obtained. Discussion: The results of genotypic analyzes were similar when compared to other studies. Conclusion: The frequency of CYP2C19 * 17 CT and TT genotypes in the group of MDD patients treated with citalopram or escitalopram was 34.5%. However, no significant association of the T allele was observed for the susceptibility of ultrafast metabolizers. However, no significant association of the T allele was observed for the susceptibility of ultrafast metabolizers.